Regulation FD Disclosure
Show detailsHide details
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Aspire Biopharma Holdings, Inc.
A biopharmaceutical company developing a sublingual (under-the-tongue) drug delivery platform that lets medications and supplements absorb quickly into the bloodstream, skipping the stomach and liver. Founded in 2021, it came to life when the earlier shell company PowerUp Acquisition Corp. merged with it in early 2025 and the combined business took the name Aspire. The name "Aspire" nods to ambition, though the company has never spelled out a story behind it—a small mystery fans of naming lore can chew on.
Warrants to purchase Class A Ordinary Shares at .50 per share, expiring March 31, 2028 — Merged with Aspire Biopharma Inc. on February 17, 2025; warrants converted from PWUPW to ASBPW
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 3.02 Unregistered Sales of Equity Securities · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
8.01 Other Events
5.07 Submission of Matters to a Vote of Security Holders
1.01 Entry into a Material Definitive Agreement · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
8.01 Other Events
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits